This Project's primary goal is to develop the use of gamma inulin-based adjuvants as safe and effective adjuvants for use in vaccines against Category A, B and C bioterrorism pathogens. As adjuvants cannot receive regulatory approval in their own right but only as part of a vaccine composition, a further objective is to develop at least one vaccine against a Category A, B or C pathogen by combining gamma inulin-based adjuvant with pathogen derived proteins or peptides. Specific components of the project include the physico-chemical characterization, and optimization of inulin-based adjuvants for use in bioterrorism subunit vaccines, determination of the mechanisms of action of inulin-based adjuvants, thereby creating the ability to develop further novel nontoxic adjuvants that utilize similar immuno-stimulatory pathways, validation of the biological activity of inulin-based adjuvants in combination with model pathogen-derived antigens (e.g. Q Fever, Shigella, flaviviruses, small pox, SARS), proof of concept studies demonstrating vaccine protection in validated animal infection models and pre-clinical safety and toxicology studies to enable inulin-based adjuvants to advance into phase 1 human trials. Although pure recombinant antigens although undoubtedly safer than whole organism vaccines, a major problem is their general lack of immunogenicity. This has created a major demand for more potent yet safe adjuvants not associated with unacceptable toxicity. Hence the urgent need for a well tolerated and effective adjuvant capable of boosting both cellular and humoral immunity. Inulin-based adjuvants offer just such advantages and should work well in combination with bioterrorism vaccines. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI061142-01
Application #
6816516
Study Section
Special Emphasis Panel (ZAI1-AR-M (M1))
Program Officer
Lambert, Linda C
Project Start
2005-08-01
Project End
2010-07-31
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$522,891
Indirect Cost
Name
Flinders University of South Australia
Department
Type
DUNS #
756172482
City
Adelaide
State
Country
Australia
Zip Code
5001
Wang, Lixin; Barclay, Thomas; Song, Yunmei et al. (2017) Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant. Vaccine 35:4382-4388
Honda-Okubo, Yoshikazu; Rajapaksha, Harinda; Sajkov, Dimitar et al. (2017) Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine. Hum Vaccin Immunother 13:1-11
Barclay, Thomas G; Rajapaksha, Harinda; Thilagam, Alagu et al. (2016) Physical characterization and in silico modeling of inulin polymer conformation during vaccine adjuvant particle formation. Carbohydr Polym 143:108-15
Hess, Jessica A; Zhan, Bin; Torigian, April R et al. (2016) The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis 10:e0004797
Sakala, Isaac G; Honda-Okubo, Yoshikazu; Fung, Johnson et al. (2016) Influenza immunization during pregnancy: Benefits for mother and infant. Hum Vaccin Immunother 12:3065-3071
Davtyan, Hayk; Zagorski, Karen; Rajapaksha, Harinda et al. (2016) Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A? pathological molecules. Sci Rep 6:28912
Gordon, David L; Sajkov, Dimitar; Honda-Okubo, Yoshikazu et al. (2016) Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant. Vaccine 34:3780-6
Petrovsky, Nikolai; Cooper, Peter D (2015) Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine 33:5920-6
Li, Lei; Honda-Okubo, Yoshikazu; Li, Connie et al. (2015) Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine. PLoS One 10:e0132003
Cooper, Peter D; Rajapaksha, K Harinda; Barclay, Thomas G et al. (2015) Inulin crystal initiation via a glucose-fructose cross-link of adjacent polymer chains: atomic force microscopy and static molecular modelling. Carbohydr Polym 117:964-72

Showing the most recent 10 out of 41 publications